NVP 231

• CAT Number: I003329
• CAS Number: 362003-83-6
• Molecular Formula: C25H25N3O2S
• Molecular Weight: 431.6
• Purity: ≥95%
• Synonyms: N-(2-benzamido-1,3-benzothiazol-6-yl)adamantane-1-carboxamide
• Target: Apoptosis
• Solubility: DMSO: ≥ 41 mg/mL
• Storage: Store at +4°C
• IC50: 12±2 nM [1]
• InChI: InChI=1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)
• InChIKey: MVSSJPGNLQPWSW-FGUCWDTJSA-N
• SMILES: O=C(C1(C[C@@H](C2)C3)C[C@H]3CC2C1)NC4=CC(SC(NC(C5=CC=CC=C5)=O)=N6)=C6C=C4

NVP 231（Cat No.:I003329）is a newly developed inhibitor of Ceramide Kinase (CerK) that shows high potency against the enzyme in vitro assays, with an IC50 value of 12 nM. CerK is a key regulator of ceramide metabolism and has been implicated in various cellular processes such as cell growth and apoptosis. NVP 231’s inhibition of CerK may have therapeutic potential for diseases associated with altered ceramide metabolism.

Reference

1:Br J Pharmacol. 2014 Dec;171(24):5829-44. doi: 10.1111/bph.12886. The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.Pastukhov O,Schwalm S,Zangemeister-Wittke U,Fabbro D,Bornancin F,Japtok L,Kleuser B,Pfeilschifter J,Huwiler A, PMID: 25134723 PMCID: PMC4290720 DOI: 10.1111/bph.12886 Abstract: BACKGROUND AND PURPOSE: Ceramide kinase (CerK) catalyzes the generation of ceramide-1-phosphate which may regulate various cellular functions, including inflammatory reactions and cell growth. Here, we studied the effect of a recently developed CerK inhibitor, NVP-231, on cancer cell proliferation and viability and investigated the role of cell cycle regulators implicated in these responses.EXPERIMENTAL APPROACH: The breast and lung cancer cell lines MCF-7 and NCI-H358 were treated with increasing concentrations of NVP-231 and DNA synthesis, colony formation and cell death were determined. Flow cytometry was performed to analyse cell cycle distribution of cells and Western blot analysis was used to detect changes in cell cycle regulator expression and activation.KEY RESULTS: In both cell lines, NVP-231 concentration-dependently reduced cell viability, DNA synthesis and colony formation. Moreover it induced apoptosis, as measured by increased DNA fragmentation and caspase-3 and caspase-9 cleavage. Cell cycle analysis revealed that NVP-231 decreased the number of cells in S phase and induced M phase arrest with an increased mitotic index, as determined by increased histone H3 phosphorylation. The effect on the cell cycle was even more pronounced when NVP-231 treatment was combined with staurosporine. Finally, overexpression of CerK protected, whereas down-regulation of CerK with siRNA sensitized, cells for staurosporine-induced apoptosis.CONCLUSIONS AND IMPLICATIONS: Our data demonstrate for the first time a crucial role for CerK in the M phase control in cancer cells and suggest its targeted inhibition, using drugs such as NVP-231, in combination with conventional pro-apoptotic chemotherapy.© 2014 The British Pharmacological Society.